Literature DB >> 9820539

Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

L H Butterfield1, S M Jilani, N G Chakraborty, L A Bui, A Ribas, V B Dissette, R Lau, S C Gamradt, J A Glaspy, W H McBride, B Mukherji, J S Economou.   

Abstract

Dendritic cells (DC) are potent stimulators of primary T cell responses. In this study, we demonstrate that DC, genetically engineered to express the MART-1/Melan-A (MART-1) tumor-associated Ag, express MART-1 mRNA and protein, correctly process and present the HLA-A2.1-restricted immunodominant MART-1 peptide (MART-1(27-35)), and serve as potent stimulators of MART-1-specific CTL in vitro. A replication-defective E1-deleted adenovirus (AdV) was constructed that expresses MART-1 (AdVMART1). Transduced DC produce full length MART-1 mRNA as well as MART-1 protein. AdVMART1 does not significantly down-regulate cell surface class I expression despite having an intact E3 region. Transduction of an HLA-A2-positive/MART-1-negative cell line with AdVMART1 renders these cells sensitive to lysis by CTL specific for the MART-1(27-35) immunodominant peptide. In addition, DC transduced with AdVMART1 stimulated MART-1(27-35)-specific tumor-infiltrating lymphocytes to synthesize IFN-gamma. Finally, AdVMART1-transduced DC were able to generate MART-1(27-35) peptide-specific, class I-restricted CTL in PBL cultures from normal donors. This study supports the use of tumor Ag-engineered DC in genetic immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820539

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 2.  Dendritic cells in melanoma immunotherapy.

Authors:  Mark B Faries; Brian J Czerniecki
Journal:  Curr Treat Options Oncol       Date:  2005-05

3.  Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.

Authors:  Yang Liu; Lisa H Butterfield; Xiaohui Fu; Zhenshun Song; Xiaoping Zhang; Chongde Lu; Guanghui Ding; Mengchao Wu
Journal:  Int J Oncol       Date:  2011-04-13       Impact factor: 5.650

4.  Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.

Authors:  Lazar Vujanovic; David E Szymkowski; Sean Alber; Simon C Watkins; Nikola L Vujanovic; Lisa H Butterfield
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

5.  Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.

Authors:  Yang Liu; Sean Daley; Viktoria N Evdokimova; David D Zdobinski; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset.

Authors:  D Rea; F H Schagen; R C Hoeben; M Mehtali; M J Havenga; R E Toes; C J Melief; R Offringa
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.

Authors:  E Ranieri; W Herr; A Gambotto; W Olson; D Rowe; P D Robbins; L S Kierstead; S C Watkins; L Gesualdo; W J Storkus
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

8.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

9.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

10.  Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Authors:  Lazar Vujanovic; Theresa L Whiteside; Douglas M Potter; Jessica Chu; Soldano Ferrone; Lisa H Butterfield
Journal:  Cancer Immunol Immunother       Date:  2008-05-17       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.